Long-term management of HIV/hepatitis C virus associated psoriasis with etanercept

Lernia, Vito Di; Zoboli, G.; Ficarelli, Elena

doi:10.4103/0378-6323.110807

Cited by 17 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, immunosuppressants, such as cyclosporine, methotrexate, and hydroxyurea and biologic agents, such as TNFα inhibitors, successfully used only in selected cases of severe refractory psoriasis at the beginning, are slowly acquiring increasing importance in this subset of patients (Cepeda et al, ; Chiricozzi et al, ; Cobo Ibáñez, Zamora, Herranz, & Steiner, ; De Simone et al, ; Di Lernia, Zoboli, & Ficarelli, ; Lee et al, ; Morar et al, ; Paparizos, Rallis, Kirsten, & Kyriakis, ; Reddy, Shah, & Wu, ). Knowledge about their safety and efficacy are limited to case‐reports, small case‐series and studies, therefore, their use has not entered the routine yet.…”

Section: Management and Treatmentmentioning

confidence: 99%

“…Biologic drugs used for psoriasis treatment in PLWH are infliximab, ustekinumab, etanercept, and apremilast (Bartke et al, ; Cepeda et al, ; Cobo Ibáñez et al, ; De Simone et al, ; Di Lernia et al, ; Gaylis, ; Kaur, Chan, & Berney, ; Linardaki, Katsarou, Ioannidou, Karafoulidou, & Boki, ; Mikhail, Weinberg, & Smith, ; Paparizos et al, ; Reddy et al, ; Sellam et al, ; Sha et al, ; Wallis et al, ).…”

Section: Management and Treatmentmentioning

confidence: 99%

“…Etanercept is a soluble p75 TNFα receptor fusion protein, successfully used to treat several PLWH unresponsive to conventional drugs. Studies have demonstrated etanercept efficacy and safety in PLWH, also in those burdened by comorbidities (Di Lernia et al, ; Kaur et al, ; Linardaki et al, ; Sha et al, ; Wallis et al, ).…”

Section: Management and Treatmentmentioning

confidence: 99%

“…Seeing that TNFα is a pro-inflammatory cytokine, the ultimate effect of these drugs is reduction of the inflammation, but they also impair appropriate immune responses to infections (Fink et al, 2017;Rustin, 2012). Di Lernia et al, 2013;Gaylis, 2003;Kaur, Chan, & Berney, 2007;Linardaki, Katsarou, Ioannidou, Karafoulidou, & Boki, 2007;Mikhail, Weinberg, & Smith, 2008;Paparizos et al, 2012;Reddy et al, 2017;Sellam et al, 2007;Sha et al, 2002;Wallis et al, 2004).…”

Section: Biologic Treatmentsmentioning

confidence: 99%

See 3 more Smart Citations

HIV‐associated psoriasis: Epidemiology, pathogenesis, and management

Ceccarelli

Rullo

Vaccaro

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

People living with HIV (PLWH) are affected by a higher incidence skin disorders, which are often associated with high morbidity and mortality. In particular, psoriasis affects PLWH severely and for a longer time than the general population. Human immunodeficiency virus (HIV) infection is characterized by a progressive decrease in CD4+ T‐cell count, and it could seem paradoxical that psoriasis exacerbations are more frequent in this subset of patients than the general population, even though it is commonly observed at any stage of infection. For a long time, there have been limited therapeutic choices for PLWH affected by psoriasis. The introduction of the combined antiretroviral therapy dramatically changed the natural course of both HIV and psoriasis in PLWH, leading to an improvement of quality and duration of life. However, the clinical severity of psoriasis in PLWH often requires the use of immunosuppressant drugs. Knowledge about their safety and efficacy are limited to case‐reports, small case‐series and studies, therefore their use has not yet entered the routine. Further studies are needed to determine if immunosuppressive drugs can be safely and effectively used in PLWH affected by psoriasis and other autoimmune disorders.

show abstract

Section: Management and Treatmentmentioning

confidence: 99%

Section: Management and Treatmentmentioning

confidence: 99%

Section: Management and Treatmentmentioning

confidence: 99%

Section: Biologic Treatmentsmentioning

confidence: 99%

See 2 more Smart Citations

HIV‐associated psoriasis: Epidemiology, pathogenesis, and management

Ceccarelli

Rullo

Vaccaro

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…The frequency of case reports and small case series in the literature has increased in recent years, demonstrating a reasonable safety profile of TNF-α inhibitors, in particular etanercept [4,5] or ustekinumab in HIV patients. CD4 and viral counts have improved or remained stable following treatment [6][7][8][9]. On the other hand, there are no reports, to our knowledge, on the treatment of psoriasis with IL-17 inhibitors in HIV patients.…”

mentioning

confidence: 99%

Secukinumab in an HIV‐positive patient with psoriasis

Lernia

Casanova

Garlassi

2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review

et al. 2017

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a relatively common autoimmune disease that is associated with progressive disability and systemic complications, with a relatively high socioeconomic burden. The treatment of RA has been revolutionized by the use of biological drugs, such as anti-tumor necrosis factor (TNF) agents. A wide spectrum of RA disease severity has been reported among patients with human immunodeficiency virus (HIV) infection. Yet, only a few cases using anti-TNF therapy have been described in this clinical population. Therefore, the aim of our case-based review was to describe the successful use of etanercept in a 38-year-old female patient with RA concomitant with HIV infection, who had been resistant to the first-line anti-rheumatic therapies. As per routine care guidelines, the patient was screened for hepatitis virus infection, latent tuberculosis, and other infectious conditions, prior to the initiation of etanercept treatment. CD4 cell count, HIV viral load, and adverse effects were closely monitored during the treatment. The HIV infection remained stable with etanercept treatment, without the need for anti-retrovirus agents. No adverse effects and serious infections were identified during the treatment. Therefore, anti-TNF therapy is a viable alternative for the treatment of RA in patients with HIV, who do not respond to conventional anti-rheumatic therapies. The relationship between TNF-α and HIV infection, as well as cautionary guidelines regarding the utilization of anti-TNF therapy in this clinical population, is discussed.

show abstract

Long-term management of HIV/hepatitis C virus associated psoriasis with etanercept

Cited by 17 publications

References 0 publications

HIV‐associated psoriasis: Epidemiology, pathogenesis, and management

HIV‐associated psoriasis: Epidemiology, pathogenesis, and management

Secukinumab in an HIV‐positive patient with psoriasis

Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review

Contact Info

Product

Resources

About